Abstract
The essence of the adaptive immune system is self tolerance, which is maintained by various central and peripheral check points. However, the tolerance mechanisms can be broken in autoimmune disease conditions due to genetic predisposition and environmental triggers. As a consequence, a patient’s tissue is attacked by his/her own adaptive immune system. An ideal therapy for autoimmune diseases should include methods to re-establish tolerance to the underpinning autoantigen(s). During the last 15 years our lab has been dedicated to developing a novel B-cell gene therapy approach for antigen-specific tolerance induction. This approach has been successfully applied to at least five different animal models for human autoimmune diseases. In this article, we will discuss many of our successful preclinical studies using the B-cell gene therapy approach to induce tolerance, as well as similar studies from others. Particular focus will be given to the tolerance induction mechanisms that have been revealed from these studies.
Keywords: Tolerance, B cells, gene therapy, immune system, self tolerance, autoimmune disease, B-cell gene therapy, environmental triggers, patient’s tissue, antigen receptors, immature lymphocytes, systemic lupus erythematosis, cancer, immune therapies, hemophilia
Infectious Disorders - Drug Targets
Title:B-Cell Based Gene Therapy for Autoimmune Diseases
Volume: 12 Issue: 3
Author(s): David W. Scott, Ai-Hong Zhang and Yan Su
Affiliation:
Keywords: Tolerance, B cells, gene therapy, immune system, self tolerance, autoimmune disease, B-cell gene therapy, environmental triggers, patient’s tissue, antigen receptors, immature lymphocytes, systemic lupus erythematosis, cancer, immune therapies, hemophilia
Abstract: The essence of the adaptive immune system is self tolerance, which is maintained by various central and peripheral check points. However, the tolerance mechanisms can be broken in autoimmune disease conditions due to genetic predisposition and environmental triggers. As a consequence, a patient’s tissue is attacked by his/her own adaptive immune system. An ideal therapy for autoimmune diseases should include methods to re-establish tolerance to the underpinning autoantigen(s). During the last 15 years our lab has been dedicated to developing a novel B-cell gene therapy approach for antigen-specific tolerance induction. This approach has been successfully applied to at least five different animal models for human autoimmune diseases. In this article, we will discuss many of our successful preclinical studies using the B-cell gene therapy approach to induce tolerance, as well as similar studies from others. Particular focus will be given to the tolerance induction mechanisms that have been revealed from these studies.
Export Options
About this article
Cite this article as:
W. Scott David, Zhang Ai-Hong and Su Yan, B-Cell Based Gene Therapy for Autoimmune Diseases, Infectious Disorders - Drug Targets 2012; 12 (3) . https://dx.doi.org/10.2174/187152612800564383
DOI https://dx.doi.org/10.2174/187152612800564383 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Interferon gama induced Tryptophan Degradation Neuropsychiatric and Immunological Consequences
Current Drug Metabolism Neuromyelitis Optica (NMO IgG+) and Genetic Susceptibility, Potential Ethnic Influences
Central Nervous System Agents in Medicinal Chemistry The Soluble CTLA-4 Receptor and its Emerging Role in Autoimmune Diseases
Current Immunology Reviews (Discontinued) Cardiac and Muscular Involvement in Idiopathic Inflammatory Myopathies: Noninvasive Diagnostic Assessment and the Role of Cardiovascular and Skeletal Magnetic Resonance Imaging
Inflammation & Allergy - Drug Targets (Discontinued) Autoimmunity-Inducing Metals (Hg, Au and Ag) Modulate Mast Cell Signaling, Function and Survival
Current Pharmaceutical Design Thiol-Dependent Cathepsins: Pathophysiological Implications and Recent Advances in Inhibitor Design
Current Pharmaceutical Design Anti-CD20 in Targeting B Lymphocytes for the Treatment of Autoimmune Diseases: Clinical Benefits and Insights into the Role of B Lymphocytes in Pathophysiology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Cytokines and their Antagonists as Therapeutic Agents
Current Medicinal Chemistry Evidence that Pregnancy Specific Glycoproteins Regulate T-Cell Function and Inflammatory Autoimmune Disease During Pregnancy
Current Drug Targets - Inflammation & Allergy Conjugates of Cell Adhesion Peptides for Therapeutics and Diagnostics Against Cancer and Autoimmune Diseases
Current Topics in Medicinal Chemistry Updates on GMSCs Treatment for Autoimmune Diseases
Current Stem Cell Research & Therapy Hepatitis C Viruss Immune Evasion Strategies
Current Immunology Reviews (Discontinued) Immune-Regulatory Mechanisms of Classical and Experimental Multiple Sclerosis Drugs: A Special Focus on Helminth-Derived Treatments
Current Medicinal Chemistry Nucleic Acids Modulate Autoimmunity Through Nucleic-Acid-Specific Toll-Like Receptors
Current Medicinal Chemistry Alopecia Areata
Recent Patents on Inflammation & Allergy Drug Discovery Computational Studies Applied to Anti-inflammatory Drug Discovery: A Review
Current Organic Chemistry CRP and Anti-CRP Autoantibodies in Systemic Lupus Erythematosus
Current Rheumatology Reviews Regulation of the Immune Response by Natural IgM: Lessons from Warm Autoimmune Hemolytic Anemia
Current Pharmaceutical Design Current and Future Therapeutic Targets of Rheumatoid Arthritis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Effect of Recombinant Human Thymosin-α1, an Immuno-Modulating Peptide with 28 Amino Acids, on the Activity of Cytochrome P450s
Drug Metabolism Letters